Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Early-stage funding slump puts more pressure on biotech startups
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic.
Nick Paul Taylor
Apr 16, 2026 7:00am
Did ‘unusually aggressive’ M&A spree trigger March IPO drought?
Apr 15, 2026 9:00am
Obsidian leverages Galera reverse merger to go public
Apr 14, 2026 11:20am
Lilly buys ADC specialist CrossBridge Bio in vague $300M deal
Apr 14, 2026 8:00am
After 3 acquisitions, Gilead shifts focus to expanded pipeline
Apr 8, 2026 4:00am
Gilead pays $3.1B for Tubulis to bolster oncology ADC pipeline
Apr 7, 2026 8:30am
